Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 63

1.

86/90Y-based theranostics targeting angiogenesis in a murine breast cancer model.

Ehlerding EB, Ferreira CA, Aluicio-Sarduy E, Jiang D, Lee HJ, Theuer CP, Engle JW, Cai W.

Mol Pharm. 2018 May 22. doi: 10.1021/acs.molpharmaceut.8b00133. [Epub ahead of print]

PMID:
29787283
2.

Cyclotron production and radiochemical separation of 55Co and 58mCo from 54Fe, 58Ni and 57Fe targets.

Valdovinos HF, Hernandez R, Graves S, Ellison PA, Barnhart TE, Theuer CP, Engle JW, Cai W, Nickles RJ.

Appl Radiat Isot. 2017 Dec;130:90-101. doi: 10.1016/j.apradiso.2017.09.005. Epub 2017 Sep 6.

PMID:
28946101
3.

Targeting angiogenesis for radioimmunotherapy with a 177Lu-labeled antibody.

Ehlerding EB, Lacognata S, Jiang D, Ferreira CA, Goel S, Hernandez R, Jeffery JJ, Theuer CP, Cai W.

Eur J Nucl Med Mol Imaging. 2018 Jan;45(1):123-131. doi: 10.1007/s00259-017-3793-2. Epub 2017 Aug 18.

PMID:
28821931
4.

Endoglin: a novel target for therapeutic intervention in acute leukemias revealed in xenograft mouse models.

Dourado KMC, Baik J, Oliveira VKP, Beltrame M, Yamamoto A, Theuer CP, Figueiredo CAV, Verneris MR, Perlingeiro RCR.

Blood. 2017 May 4;129(18):2526-2536. doi: 10.1182/blood-2017-01-763581. Epub 2017 Mar 28.

5.

ImmunoPET and Near-Infrared Fluorescence Imaging of Pancreatic Cancer with a Dual-Labeled Bispecific Antibody Fragment.

Luo H, England CG, Goel S, Graves SA, Ai F, Liu B, Theuer CP, Wong HC, Nickles RJ, Cai W.

Mol Pharm. 2017 May 1;14(5):1646-1655. doi: 10.1021/acs.molpharmaceut.6b01123. Epub 2017 Mar 24.

6.

Engineering Intrinsically Zirconium-89 Radiolabeled Self-Destructing Mesoporous Silica Nanostructures for In Vivo Biodistribution and Tumor Targeting Studies.

Goel S, Chen F, Luan S, Valdovinos HF, Shi S, Graves SA, Ai F, Barnhart TE, Theuer CP, Cai W.

Adv Sci (Weinh). 2016 May 27;3(11):1600122. eCollection 2016 Nov.

7.

Dual Targeting of Tissue Factor and CD105 for Preclinical PET Imaging of Pancreatic Cancer.

Luo H, England CG, Shi S, Graves SA, Hernandez R, Liu B, Theuer CP, Wong HC, Nickles RJ, Cai W.

Clin Cancer Res. 2016 Aug 1;22(15):3821-30. doi: 10.1158/1078-0432.CCR-15-2054. Epub 2016 Mar 29.

8.

Endoglin targeting inhibits tumor angiogenesis and metastatic spread in breast cancer.

Paauwe M, Heijkants RC, Oudt CH, van Pelt GW, Cui C, Theuer CP, Hardwick JC, Sier CF, Hawinkels LJ.

Oncogene. 2016 Aug 4;35(31):4069-79. doi: 10.1038/onc.2015.509. Epub 2016 Jan 25.

PMID:
26804178
9.

High Yield Production and Radiochemical Isolation of Isotopically Pure Arsenic-72 and Novel Radioarsenic Labeling Strategies for the Development of Theranostic Radiopharmaceuticals.

Ellison PA, Barnhart TE, Chen F, Hong H, Zhang Y, Theuer CP, Cai W, Nickles RJ, DeJesus OT.

Bioconjug Chem. 2016 Jan 20;27(1):179-88. doi: 10.1021/acs.bioconjchem.5b00592. Epub 2015 Dec 22.

10.

Noninvasive brain cancer imaging with a bispecific antibody fragment, generated via click chemistry.

Luo H, Hernandez R, Hong H, Graves SA, Yang Y, England CG, Theuer CP, Nickles RJ, Cai W.

Proc Natl Acad Sci U S A. 2015 Oct 13;112(41):12806-11. doi: 10.1073/pnas.1509667112. Epub 2015 Sep 28.

11.

Novel Preparation Methods of (52)Mn for ImmunoPET Imaging.

Graves SA, Hernandez R, Fonslet J, England CG, Valdovinos HF, Ellison PA, Barnhart TE, Elema DR, Theuer CP, Cai W, Nickles RJ, Severin GW.

Bioconjug Chem. 2015 Oct 21;26(10):2118-24. doi: 10.1021/acs.bioconjchem.5b00414. Epub 2015 Sep 10.

12.

PET Imaging of Abdominal Aortic Aneurysm with 64Cu-Labeled Anti-CD105 Antibody Fab Fragment.

Shi S, Orbay H, Yang Y, Graves SA, Nayak TR, Hong H, Hernandez R, Luo H, Goel S, Theuer CP, Nickles RJ, Cai W.

J Nucl Med. 2015 Jun;56(6):927-32. doi: 10.2967/jnumed.114.153098. Epub 2015 Apr 16.

13.

In Vivo Tumor Vasculature Targeting of CuS@MSN Based Theranostic Nanomedicine.

Chen F, Hong H, Goel S, Graves SA, Orbay H, Ehlerding EB, Shi S, Theuer CP, Nickles RJ, Cai W.

ACS Nano. 2015;9(4):3926-34. doi: 10.1021/nn507241v. Epub 2015 Apr 8.

14.

Red fluorescent zinc oxide nanoparticle: a novel platform for cancer targeting.

Hong H, Wang F, Zhang Y, Graves SA, Eddine SB, Yang Y, Theuer CP, Nickles RJ, Wang X, Cai W.

ACS Appl Mater Interfaces. 2015 Feb 11;7(5):3373-81. doi: 10.1021/am508440j. Epub 2015 Jan 29.

15.

An open-label phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) with bevacizumab in patients with advanced cancer.

Gordon MS, Robert F, Matei D, Mendelson DS, Goldman JW, Chiorean EG, Strother RM, Seon BK, Figg WD, Peer CJ, Alvarez D, Adams BJ, Theuer CP, Rosen LS.

Clin Cancer Res. 2014 Dec 1;20(23):5918-26. doi: 10.1158/1078-0432.CCR-14-1143. Epub 2014 Sep 26.

16.

Effects of the combination of TRC105 and bevacizumab on endothelial cell biology.

Liu Y, Tian H, Blobe GC, Theuer CP, Hurwitz HI, Nixon AB.

Invest New Drugs. 2014 Oct;32(5):851-9. doi: 10.1007/s10637-014-0129-y. Epub 2014 Jul 5.

17.

In vivo tumor vasculature targeted PET/NIRF imaging with TRC105(Fab)-conjugated, dual-labeled mesoporous silica nanoparticles.

Chen F, Nayak TR, Goel S, Valdovinos HF, Hong H, Theuer CP, Barnhart TE, Cai W.

Mol Pharm. 2014 Nov 3;11(11):4007-14. doi: 10.1021/mp500306k. Epub 2014 Jun 25.

18.

Engineering of hollow mesoporous silica nanoparticles for remarkably enhanced tumor active targeting efficacy.

Chen F, Hong H, Shi S, Goel S, Valdovinos HF, Hernandez R, Theuer CP, Barnhart TE, Cai W.

Sci Rep. 2014 May 30;4:5080. doi: 10.1038/srep05080.

19.

Theranostic unimolecular micelles based on brush-shaped amphiphilic block copolymers for tumor-targeted drug delivery and positron emission tomography imaging.

Guo J, Hong H, Chen G, Shi S, Nayak TR, Theuer CP, Barnhart TE, Cai W, Gong S.

ACS Appl Mater Interfaces. 2014 Dec 24;6(24):21769-79. doi: 10.1021/am5002585. Epub 2014 Mar 14.

20.

Modulation of circulating protein biomarkers following TRC105 (anti-endoglin antibody) treatment in patients with advanced cancer.

Liu Y, Starr MD, Brady JC, Dellinger A, Pang H, Adams B, Theuer CP, Lee NY, Hurwitz HI, Nixon AB.

Cancer Med. 2014 Jun;3(3):580-91. doi: 10.1002/cam4.207. Epub 2014 Feb 14.

21.

Positron emission tomography imaging of CD105 expression in a rat myocardial infarction model with (64)Cu-NOTA-TRC105.

Orbay H, Zhang Y, Valdovinos HF, Song G, Hernandez R, Theuer CP, Hacker TA, Nickles RJ, Cai W.

Am J Nucl Med Mol Imaging. 2013 Dec 15;4(1):1-9. eCollection 2013.

22.

Pravastatin stimulates angiogenesis in a murine hindlimb ischemia model: a positron emission tomography imaging study with (64)Cu-NOTA-TRC105.

Orbay H, Hong H, Koch JM, Valdovinos HF, Hacker TA, Theuer CP, Barnhart TE, Cai W.

Am J Transl Res. 2013 Dec 1;6(1):54-63. eCollection 2013.

23.

In vivo tumor targeting and image-guided drug delivery with antibody-conjugated, radiolabeled mesoporous silica nanoparticles.

Chen F, Hong H, Zhang Y, Valdovinos HF, Shi S, Kwon GS, Theuer CP, Barnhart TE, Cai W.

ACS Nano. 2013 Oct 22;7(10):9027-39. doi: 10.1021/nn403617j. Epub 2013 Oct 1.

24.

Image-guided and tumor-targeted drug delivery with radiolabeled unimolecular micelles.

Guo J, Hong H, Chen G, Shi S, Zheng Q, Zhang Y, Theuer CP, Barnhart TE, Cai W, Gong S.

Biomaterials. 2013 Nov;34(33):8323-8332. doi: 10.1016/j.biomaterials.2013.07.085. Epub 2013 Aug 8.

25.

Positron emission tomography imaging of angiogenesis in a murine hindlimb ischemia model with 64Cu-labeled TRC105.

Orbay H, Zhang Y, Hong H, Hacker TA, Valdovinos HF, Zagzebski JA, Theuer CP, Barnhart TE, Cai W.

Mol Pharm. 2013 Jul 1;10(7):2749-56. doi: 10.1021/mp400191w. Epub 2013 Jun 17.

26.

Imaging tumor angiogenesis in breast cancer experimental lung metastasis with positron emission tomography, near-infrared fluorescence, and bioluminescence.

Zhang Y, Hong H, Nayak TR, Valdovinos HF, Myklejord DV, Theuer CP, Barnhart TE, Cai W.

Angiogenesis. 2013 Jul;16(3):663-74. doi: 10.1007/s10456-013-9344-y. Epub 2013 Mar 8. Erratum in: Angiogenesis. 2013 Oct;16(4):993-4.

27.

Tumor vasculature targeting and imaging in living mice with reduced graphene oxide.

Shi S, Yang K, Hong H, Valdovinos HF, Nayak TR, Zhang Y, Theuer CP, Barnhart TE, Liu Z, Cai W.

Biomaterials. 2013 Apr;34(12):3002-9. doi: 10.1016/j.biomaterials.2013.01.047. Epub 2013 Jan 29.

28.

PET imaging of CD105/endoglin expression with a ⁶¹/⁶⁴Cu-labeled Fab antibody fragment.

Zhang Y, Hong H, Orbay H, Valdovinos HF, Nayak TR, Theuer CP, Barnhart TE, Cai W.

Eur J Nucl Med Mol Imaging. 2013 May;40(5):759-67. doi: 10.1007/s00259-012-2334-2. Epub 2013 Jan 24.

29.

Positron emission tomography imaging of tumor angiogenesis with a (61/64)Cu-labeled F(ab')(2) antibody fragment.

Hong H, Zhang Y, Orbay H, Valdovinos HF, Nayak TR, Bean J, Theuer CP, Barnhart TE, Cai W.

Mol Pharm. 2013 Feb 4;10(2):709-16. doi: 10.1021/mp300507r. Epub 2013 Jan 14.

30.

A phase 1 study of TRC102, an inhibitor of base excision repair, and pemetrexed in patients with advanced solid tumors.

Gordon MS, Rosen LS, Mendelson D, Ramanathan RK, Goldman J, Liu L, Xu Y, Gerson SL, Anthony SP, Figg WD, Spencer S, Adams BJ, Theuer CP, Leigh BR, Weiss GJ.

Invest New Drugs. 2013 Jun;31(3):714-23. doi: 10.1007/s10637-012-9876-9. Epub 2012 Sep 29.

PMID:
23054206
31.

A phase I first-in-human study of TRC105 (Anti-Endoglin Antibody) in patients with advanced cancer.

Rosen LS, Hurwitz HI, Wong MK, Goldman J, Mendelson DS, Figg WD, Spencer S, Adams BJ, Alvarez D, Seon BK, Theuer CP, Leigh BR, Gordon MS.

Clin Cancer Res. 2012 Sep 1;18(17):4820-9. doi: 10.1158/1078-0432.CCR-12-0098. Epub 2012 Jul 5.

32.

Positron emission tomography imaging of tumor angiogenesis with a 66Ga-labeled monoclonal antibody.

Engle JW, Hong H, Zhang Y, Valdovinos HF, Myklejord DV, Barnhart TE, Theuer CP, Nickles RJ, Cai W.

Mol Pharm. 2012 May 7;9(5):1441-8. doi: 10.1021/mp300019c. Epub 2012 Apr 21.

33.

In vivo targeting and positron emission tomography imaging of tumor vasculature with (66)Ga-labeled nano-graphene.

Hong H, Zhang Y, Engle JW, Nayak TR, Theuer CP, Nickles RJ, Barnhart TE, Cai W.

Biomaterials. 2012 Jun;33(16):4147-56. doi: 10.1016/j.biomaterials.2012.02.031. Epub 2012 Mar 3.

34.

In vivo targeting and imaging of tumor vasculature with radiolabeled, antibody-conjugated nanographene.

Hong H, Yang K, Zhang Y, Engle JW, Feng L, Yang Y, Nayak TR, Goel S, Bean J, Theuer CP, Barnhart TE, Liu Z, Cai W.

ACS Nano. 2012 Mar 27;6(3):2361-70. doi: 10.1021/nn204625e. Epub 2012 Feb 16.

35.

Positron emission tomography and optical imaging of tumor CD105 expression with a dual-labeled monoclonal antibody.

Zhang Y, Hong H, Engle JW, Yang Y, Theuer CP, Barnhart TE, Cai W.

Mol Pharm. 2012 Mar 5;9(3):645-53. doi: 10.1021/mp200592m. Epub 2012 Jan 31.

36.

Increased epithelial cadherin expression among Japanese intestinal-type gastric cancers compared with specimens from American patients of European descent.

Theuer CP, Al-Kuran R, Akiyama Y, Okumura M, Ziogas A, Carpenter PM.

Am Surg. 2006 Apr;72(4):332-8.

PMID:
16676859
37.

Gender and race/ethnicity affect the cost-effectiveness of colorectal cancer screening.

Theuer CP, Taylor TH, Brewster WR, Anton-Culver H.

J Natl Med Assoc. 2006 Jan;98(1):51-7.

38.

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma.

Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, Ginsberg MS, Kim ST, Baum CM, DePrimo SE, Li JZ, Bello CL, Theuer CP, George DJ, Rini BI.

J Clin Oncol. 2006 Jan 1;24(1):16-24. Epub 2005 Dec 5.

PMID:
16330672
39.

Radioimmunotherapy of non-Hodgkin's lymphoma: clinical development of the Zevalin regimen.

Theuer CP, Leigh BR, Multani PS, Allen RS, Liang BC.

Biotechnol Annu Rev. 2004;10:265-95. Review.

PMID:
15504711
40.

Ethnicity-related gastric cancer survival.

Theuer CP.

J Clin Oncol. 2003 Nov 15;21(22):4253; author reply 4253. No abstract available.

PMID:
14615460
41.

CD8+ T-cell mediated tumor protection by Pseudomonas exotoxin fused to ovalbumin in C57BL/6 mice.

Becerra JC, Arthur JF, Landucci GR, Forthal DN, Theuer CP.

Surgery. 2003 Apr;133(4):404-10.

PMID:
12717358
42.

Paranuaclear E-cadherin in gastric adenocarcinoma.

Carpenter PM, Al-Kuran RA, Theuer CP.

Am J Clin Pathol. 2002 Dec;118(6):887-94.

PMID:
12472282
43.

Microsatellite instability in Japanese vs European American patients with gastric cancer.

Theuer CP, Campbell BS, Peel DJ, Lin F, Carpenter P, Ziogas A, Butler JA.

Arch Surg. 2002 Aug;137(8):960-5; discussion 965-6.

PMID:
12146999
44.

The topography of colorectal cancer varies by race/ethnicity and affects the utility of flexible sigmoidoscopy.

Theuer CP, Taylor TH, Brewster WR, Campbell BS, Becerra JC, Anton-Culver H.

Am Surg. 2001 Dec;67(12):1157-61.

PMID:
11768820
45.

The role of oral contrast administration immediately prior to the computed tomographic evaluation of the blunt trauma victim.

Nastanski F, Cohen A, Lush SP, DiStante A, Theuer CP.

Injury. 2001 Sep;32(7):545-9.

PMID:
11524086
46.

Racial and ethnic colorectal cancer patterns affect the cost-effectiveness of colorectal cancer screening in the United States.

Theuer CP, Wagner JL, Taylor TH, Brewster WR, Tran D, McLaren CE, Anton-Culver H.

Gastroenterology. 2001 Mar;120(4):848-56.

PMID:
11231939
47.

Screening for colorectal cancer.

Theuer CP, Taylor TH, Anton-Culver H.

N Engl J Med. 2000 Nov 30;343(22):1652-4. No abstract available.

PMID:
11184982
48.
50.

Signet ring cell histology is associated with unique clinical features but does not affect gastric cancer survival.

Theuer CP, Nastanski F, Brewster WR, Butler JA, Anton-Culver H.

Am Surg. 1999 Oct;65(10):915-21.

PMID:
10515534

Supplemental Content

Loading ...
Support Center